Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Brief Summary: The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not respond to prior peginterferon/ribavirin therapy or are HCV treatment-naive (patients who never received treatment for HCV infection).


Options:
A: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated Interferon alfa-2b, Drug: Ribavirin, Drug: Sofosbuvir | Arm Label: Simeprevir + Sofosbuvir; Type: EXPERIMENTAL; Interventions: Drug: Simeprevir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Pegylated Interferon alfa-2b; Assigned to Arm(s): Standard | Intervention Type: DRUG; Name: Simeprevir; Assigned to Arm(s): Simeprevir + Sofosbuvir | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Standard | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Simeprevir + Sofosbuvir, Standard
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: PSI-7977 (GS7977); Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1, Arm 3
C: Arm Label: LDV/SOF 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 12 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 Week, LDV/SOF 8 Week, LDV/SOF+RBV 8 Week | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 8 Week
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207217 | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335 | Arm Label: 8; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 9; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 10; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 11; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 207127, Drug: BI 201335 | Arm Label: 12; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207217; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 10

Answer: B